{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:24:41Z","timestamp":1756682681574,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Brazilian Society of Rheumatology","award":["."],"award-info":[{"award-number":["."]}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"crossref","award":["2021\/04892-0","2019\/11367-9","2019\/11776-6"],"award-info":[{"award-number":["2021\/04892-0","2019\/11367-9","2019\/11776-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["303379\/2018-9"],"award-info":[{"award-number":["303379\/2018-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Currently, only a few retrospective cohort or cross-sectional studies have described the general characteristics of Brazilian patients with classical dermatomyositis (DM). In contrast, we aimed to longitudinally assess a large sample of these patients, and several myositis autoantibodies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center longitudinal study included 91 Brazilian adults with defined DM (EULAR\/ACR 2017) who underwent follow-up appointments in our tertiary center from 2012 to 2021. Myositis autoantibody analysis was performed using a commercial kit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of the patients was 47.3\u2009\u00b1\u200915.4\u00a0years, with a predominance of female (67.0%) and White (81.3%) patients. As an initial treatment, 76.9% of the patients received methylprednisolone pulse therapy, 59.3% received intravenous immunoglobulin, and 54.9% received both drugs. The median follow-up duration was 44\u00a0months (interquartile 17\u201367) months. There were 92 severe episodes of infection, and neoplasms were identified in 20 patients (22.0%). Hypertension was identified in 46.2% of patients, whereas diabetes mellitus and myocardial infarction occurred in 19.8% and 4.4%, respectively. Nine patients died during the follow-up. At the last visit, one-third of the patients had disease activity, half had a complete clinical response, and one-fifth were in disease remission. In a univariate logistic regression, anti-aminoacyl-tRNA synthetase antibodies (n\u2009=\u200913) were associated with interstitial lung disease, \u201cmechanic\u2019s hands\u201d, and anti-Ro-52, and had an inverse association with \u201cV\u201d-neck and \u201cshawl\u201d signs. Anti-MDA-5 (n\u2009=\u200910) were associated with male gender, digital ulcers, vasculitis, arthritis, anti-Ro-52, and active disease. Anti-Ro-52 (n\u2009=\u200926) were associated with \u201cmechanics\u2019 hands\u201d, arthritis, interstitial lung disease, anti-tRNA synthetases, and anti-MDA-5. No association was found for anti-Mi-2 (n\u2009=\u200910).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study shows the general profile of a significant sample of Brazilian patients with DM as well as the association of some antibodies with clinical and laboratory manifestations of this myositis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-022-00276-x","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T09:03:04Z","timestamp":1668243784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study"],"prefix":"10.1186","volume":"62","author":[{"given":"Nat\u00e1ssia Cristina Carboni","family":"Truzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Santos","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela Bruna Pires","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Henrique Carlos","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3682-4517","authenticated-orcid":false,"given":"Samuel Katsuyuki","family":"Shinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"276_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734\u201347.","journal-title":"N Engl J Med"},{"key":"276_CR2","first-page":"256","volume":"153","author":"P Sena","year":"2018","unstructured":"Sena P, Gianatti A, Gambini D. Dermatomyositis: clinicopathological correlations. G Ital Dermatol Venereol. 2018;153:256\u201364.","journal-title":"G Ital Dermatol Venereol"},{"key":"276_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.46833\/reumatologiasp.2017.16.4.6-11","volume":"16","author":"SK Shinjo","year":"2017","unstructured":"Shinjo SK. Miopatias autoimunes sist\u00eamicas. Rev Paul Reumatol. 2017;16:6\u201311.","journal-title":"Rev Paul Reumatol"},{"key":"276_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1051\/medsci\/2019178","volume":"35","author":"L Bolko","year":"2019","unstructured":"Bolko L, Gitiaux C, Allenbach Y. Dermatomyosites nouveaux anticorps, nouvelle classification. M\u00e9decine\/Sciences. 2019;35:18\u201323.","journal-title":"M\u00e9decine\/Sciences"},{"key":"276_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28.","journal-title":"Curr Rheumatol Rep"},{"key":"276_CR6","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1097\/RHU.0000000000001756","volume":"28","author":"PA Olivo Pallo","year":"2021","unstructured":"Olivo Pallo PA, Hoff LS, Borges IBP, et al. Characterization of patients with dermatomyositis according to anti-melanoma differentiation-associated gene-5 autoantibodies in centers of 3 Latin American countries. J Clin Rheumatol. 2021;28:e444\u20138.","journal-title":"J Clin Rheumatol"},{"key":"276_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/abd1806-4841.20186803","volume":"93","author":"IBP Borges","year":"2018","unstructured":"Borges IBP, Silva MG, Shinjo SK. Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis. An Bras Dermatol. 2018;93:517\u201323.","journal-title":"An Bras Dermatol"},{"key":"276_CR8","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum. 2013;65:2954\u201362.","journal-title":"Arthritis Rheum"},{"key":"276_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","volume":"36","author":"P Srivastava","year":"2016","unstructured":"Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int. 2016;36:935\u201343.","journal-title":"Rheumatol Int"},{"key":"276_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.1780280711","volume":"28","author":"IN Targoff","year":"1985","unstructured":"Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28:796\u2013803.","journal-title":"Arthritis Rheum"},{"key":"276_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis. Arch Dermatol. 2011;147:391\u20138.","journal-title":"Arch Dermatol"},{"key":"276_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72:449\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"276_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jdermsci.2005.09.004","volume":"40","author":"K Komura","year":"2005","unstructured":"Komura K, Fujimoto M, Matsushita T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005;40:215\u20137.","journal-title":"J Dermatol Sci"},{"key":"276_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s42358-019-0071-y","volume":"59","author":"MIC dos Passos Carvalho","year":"2019","unstructured":"dos Passos Carvalho MIC, Shinjo SK. Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis. Adv Rheumatol. 2019;59:27.","journal-title":"Adv Rheumatol"},{"key":"276_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s42358-021-00171-x","volume":"61","author":"VP de Andrade","year":"2021","unstructured":"de Andrade VP, De Souza FHC, Behrens Pinto GL, et al. The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis. Adv Rheumatol. 2021;61:12.","journal-title":"Adv Rheumatol"},{"key":"276_CR16","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar2276","volume":"9","author":"M Koenig","year":"2007","unstructured":"Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78.","journal-title":"Arthritis Res Ther"},{"key":"276_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"M Cruellas","year":"2013","unstructured":"Cruellas M, Viana V, Levy-Neto M, et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics. 2013;68:909\u201314.","journal-title":"Clinics"},{"key":"276_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","volume":"23","author":"S Sato","year":"2013","unstructured":"Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496\u2013502.","journal-title":"Mod Rheumatol"},{"key":"276_CR19","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy L-A, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307\u201315.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"276_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5114\/reum.2016.58756","volume":"1","author":"A Masiak","year":"2016","unstructured":"Masiak A, Kulczycka J, Czuszy\u0144ska Z, et al. Clinical characteristics of patients with anti-TIF1-\u03b3 antibodies. Rheumatology. 2016;1:14\u20138.","journal-title":"Rheumatology"},{"key":"276_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69:1771\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"276_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68:689\u201394.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"276_CR23","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-\u03b3 antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49:1726\u201333.","journal-title":"Rheumatology"},{"key":"276_CR24","doi-asserted-by":"publisher","first-page":"19551964","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:19551964.","journal-title":"Ann Rheum Dis"},{"key":"276_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626\u201336.","journal-title":"J Am Acad Dermatol"},{"key":"276_CR26","doi-asserted-by":"crossref","unstructured":"Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: nerve injuries research committee. His Majesty\u2019s Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous. Brain. 2010;133:28382844.","DOI":"10.1093\/brain\/awq270"},{"issue":"9","key":"276_CR27","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/art.21291","volume":"52","author":"CV Oddis","year":"2005","unstructured":"Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52(9):2607\u201315.","journal-title":"Arthritis Rheum"},{"key":"276_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Bendewald","year":"2010","unstructured":"Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010;146:26\u201330.","journal-title":"Arch Dermatol"},{"key":"276_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"276_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1590\/S0482-50042012000600008","volume":"52","author":"FHC de Souza","year":"2012","unstructured":"de Souza FHC, Barros TBM, Levy-Neto M, et al. Adult dermatomyositis: experience of Brazilian tertiary care center. Rev Bras Reumatol. 2012;52:897\u2013902.","journal-title":"Rev Bras Reumatol"},{"key":"276_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10067-005-1164-z","volume":"25","author":"A Airio","year":"2006","unstructured":"Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006;25:234\u20139.","journal-title":"Clin Rheumatol"},{"key":"276_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379\u201387.","journal-title":"Am J Med"},{"key":"276_CR33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00296-019-04254-3","volume":"39","author":"JM de Souza","year":"2019","unstructured":"de Souza JM, Hoff LS, Shinjo SK. Intravenous human immunoglobulin and\/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies. Rheumatol Int. 2019;39:1201\u201312.","journal-title":"Rheumatol Int"},{"key":"276_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/rheumatology\/keab597","volume":"61","author":"LS Hoff","year":"2022","unstructured":"Hoff LS, de Souza FHC, Miossi R, et al. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology. 2022;61:1579\u201388.","journal-title":"Rheumatology"},{"key":"276_CR35","first-page":"1011","volume":"35","author":"RC de Souza","year":"2017","unstructured":"de Souza RC, de Souza FHC, Miossi R, et al. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. Clin Exp Rheumatol. 2017;35:1011\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"276_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s42358-019-0048-x","volume":"59","author":"FHC de Souza","year":"2019","unstructured":"de Souza FHC, de Ara\u00fajo DB, Vilela VS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol. 2019;59:6.","journal-title":"Adv Rheumatol"},{"key":"276_CR37","first-page":"82","volume":"32","author":"FHC de Souza","year":"2014","unstructured":"de Souza FHC, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol. 2014;32:82\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"276_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/290797","volume":"2014","author":"M Labrador-Horrillo","year":"2014","unstructured":"Labrador-Horrillo M, Martinez MA, Selva-O\u2019Callaghan A, et al. Anti-MDA5 antibodies in a large mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:1\u20138.","journal-title":"J Immunol Res."},{"key":"276_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.6061\/clinics\/2016(12)06","volume":"71","author":"MG Silva","year":"2016","unstructured":"Silva MG, Borga EF, Mello SB, Shinjo SK. Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients. Clinics (Sao Paulo). 2016;71:709\u201314.","journal-title":"Clinics (Sao Paulo)"},{"key":"276_CR40","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/acr.21879","volume":"65","author":"MT De Moraes","year":"2013","unstructured":"De Moraes MT, De Souza FH, De Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hokoben). 2013;65:793\u20139.","journal-title":"Arthritis Care Res (Hokoben)"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-022-00276-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-022-00276-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-022-00276-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T09:15:11Z","timestamp":1668244511000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-022-00276-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/s42358-022-00276-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"type":"electronic","value":"2523-3106"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee (CAAE 68523717.1.0000.0068), and all participants signed the term free and informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}